Revenue segments as reported by the company.

Diagnostics

Drug Development

Intercompany eliminations and other

Biopharma Laboratory Services

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative expenses

Amortization of intangibles and other assets

Goodwill and other asset impairments

Restructuring and other charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Labcorp Holdings Inc

Laboratory Corp. of America Holdings operates as a life sciences company, which engages in the provision of vital information to help health professionals make clear and confident decisions. It operates through the Drug Development and Diagnostics segments. The Drug Development segment consists of lead optimization, preclinical safety assessment, analytical services, clinical trials, central laboratories, biomarkers, and companion diagnostics, market access, and technology solutions. The Diagnostics segment includes primary care, women's health, specialty medicine, oncology, ACOs, and hospitals and health systems. The company was founded in 1971 and is headquartered in Burlington, NC.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Labcorp posts strong Q4 results, eyes growth amid strategic moves

Labcorp's Q4 performance reflects resilience and growth potential in Diagnostics and Drug Development
Strategic initiatives and spinoff plans position Labcorp for future success and market leadership
Challenges in cost management and revenue growth require focused strategies for sustainable growth
Opportunities lie in capital deployment, market expansion, and operational enhancements for Labcorp

Labcorp reports strong Q1 results, eyes growth amid challenges

Labcorp's Q1 2023 performance was strong, driven by Diagnostics base business revenue growth and strategic initiatives.
While facing challenges like margin constraints and revenue declines in Drug Development, Labcorp is focusing on sustained growth and market opportunities.
The company's emphasis on digital health, upcoming Investor Days, and robust M&A pipeline showcase a proactive approach to future growth.
Labcorp's cautious optimism for SALSA approval and continued advocacy for legislation position it well for potential impacts and future developments.

Labcorp reports robust Q2 earnings, eyes global expansion opportunities

Labcorp's Q2 performance was strong, with revenue growth and strategic initiatives driving positive results.
Challenges such as supply constraints and margin expectations were addressed, with a focus on capital allocation and growth opportunities.
The company remains optimistic about future prospects, with expansion plans, enhanced disclosures, and consistent guidance for segments.
Investor Day scheduled for September to provide more insights, reflecting Labcorp's commitment to transparency and growth.

Labcorp reports robust Q3 earnings, eyes growth amid regulatory challenges

Labcorp's Q3 performance was strong, with a focus on revenue growth, strategic partnerships, and new test introductions. Despite challenges from regulatory impacts, the company remains optimistic about driving substantial shareholder value through growth opportunities and cost-saving initiatives.

LabCorp reports robust Q4 earnings, eyes growth in strategic areas

LabCorp's Q4 call showcased strong financials, strategic partnerships, and innovative offerings. Challenges include pricing issues in Biopharma and COVID impacts on Diagnostics. Opportunities for growth through capital allocation and focus on larger pharma in Biopharma.

LabCorp reports robust Q1 earnings, eyes margin improvement in 2024

LabCorp's Q1 2024 earnings call highlighted strong financial performance, strategic acquisitions, and plans for margin improvement. Despite challenges in certain business areas, the company remains focused on profitable growth and innovation in specialty testing.

Labcorp reports robust Q2 earnings, eyes growth through innovation

Labcorp's Q2 2024 earnings reflect a strong performance, marked by revenue growth, strategic acquisitions, and innovation in healthcare solutions.
While facing challenges in certain segments, Labcorp's focus on expansion, new tests, and digital solutions positions it well for future growth and market leadership.
With a clear outlook for growth and a commitment to advancing healthcare, Labcorp remains a key player in the diagnostics and biopharma laboratory services industry.

Labcorp reports robust Q3 earnings, eyes growth through strategic partnerships

Labcorp's Q3 2024 performance reflects strong revenue growth and profitability, driven by Diagnostics and Biopharma services.
Despite challenges such as regulatory delays, the company remains focused on strategic growth initiatives and operational efficiency.
With a positive outlook for continued growth, Labcorp's emphasis on partnerships, innovation, and cost-saving measures bodes well for its long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Labcorp Holdings, Inc. engages in providing medical testing services. The company was founded on April 16, 2024 and is headquartered in Burlington, NC.

LabCorp (LH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

LabCorp (LH) Expected to Beat Earnings Estimates: Should You Buy?

As of late, it has definitely been a great time to be an investor of Laboratory Corporation of America

Will Laboratory Corporation of America Continue to Surge Higher?

LabCorp's (LH) developments to support COVID-19 testing are believed to have contributed to the company's second-quarter earnings.

Growing Testing Capacity to Aid LabCorp's (LH) Q2 Earnings?

Quest Diagnostics

Moderna

Novavax

Pfizer

Regeneron Pharmaceuticals

Sanofi

COVID-19 crushed the stock market in March. The only real survivors were companies involved with testing, treatments and vaccines.

8 Coronavirus Stocks That Can Deliver Even More Upside Ahead

One of the most important aspects of reopening the economy during this pandemic is testing for COVID-19.

COVID-19 Testing Creates a Boom for LabCorp and Quest Diagnostics

Anthem

Patterson Companies

Here we look at three stocks that investors can add to their watchlist backed by robust long-term prospects.

3 GARP MedTech Stocks to Beat Pandemic-Led Market Volatility

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company deeply integrated in guiding patient care, has launched Insight Analytics™ reports that support provider organizations delivering improved care, both individually and on a population level, for a range of high-risk health conditions. The reports, which reflect LabCorp’s deep analytical expertise, combine national laboratory test values with patient demographics to help identify high-risk patients, clos

LabCorp’s Insight Analytics Reports Help Healthcare Organizations Identify Trends for High-Risk Health Conditions and Improve Quality of Care

LabCorp (LH) claims this to be the first digital COVID-19 service that physicians can use to remotely diagnose patients before any surgery or procedure.

LabCorp Launches At-Home Coronavirus Test Collection Kit

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH) today launched the LabCorp At Home COVID-19 Test Collection Service, the first seamless digital service aimed at helping doctors protect patients by testing them for COVID-19 before surgeries and other important treatments. The service received Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) on July 1, 2020. The service enables a doctor to directly order a LabCorp At Home COVID-19 test collection kit for thei

LabCorp Launches First Digital COVID-19 Service That Improves the Doctor and Patient Experience

Cerner

Once the pandemic-led crisis eases, these MedTech stocks will likely flourish on the back of number of positive developments.

3 Cheap MedTech Stocks Set to Gain Once Coronavirus Crisis Ebbs

Hologic

Here are some MedTech stocks which might be a solid investment option post the coronavirus blues.

4 Cheap MedTech Stocks Poised to Beat Industry Post-Pandemic

This solution by LabCorp (LH) takes the idea from Covance's COVID-19 Operational Recovery Team to better understand the necessities.

LabCorp's Xcellerate Coronavirus Solution to Aid Clinical R&D

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that Covance, its drug development business, has deployed the Xcellerate® COVID-19 solution as part of its award-winning Xcellerate platform. Covance has developed a comprehensive approach to reinitiate ongoing research and start up new studies, with a focus on patient safety and study delivery. Designed in conjunction with Covance’s CO

LabCorp Introduces Xcellerate® COVID-19 Clinical Study Solution

The information related to neutralizing antibody test of LabCorp (LH) can also be used for the screening of convalescent plasma for prophylactic and therapeutic use.

LabCorp Neutralizing Antibody Test to Aid Coronavirus Vaccine R&D

The diagnostics industry leader's PhenoSense assay will also gauge how well a patient's antibodies will fare in fighting off SAR-CoV-2.

LabCorp Launches New Coronavirus Antibody Test

BURLINGTON, N.C.--(BUSINESS WIRE)--LabCorp (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced the launch of a new test that can be used to assess the capacity of antibodies in patient plasma to inhibit the SARS-CoV-2 virus. This information could be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use. This neutralizing antibody test will be available to bioph

LabCorp Launches New Neutralizing Antibody Test

Alpha Pro Tech

CVS Health

OPKO Health

I have previously discussed my views of the coronavirus pandemic, which included the fact that many states opened too early and that greater testing was needed.

The New Normal Of The Coronavirus Pandemic: Investment Implications

Abbott Labs

Illumina

QIAGEN

Amid the pandemic, these four companies with strong diagnostics testing developments might show better resilience.

Coronavirus Diagnostic Tests in High Demand: 4 Stocks in Focus

AmerisourceBergen

Align Technology

Becton, Dickinson and Co.

Cardinal Health

Cooper Companies

Henry Schein

McKesson

DENTSPLY SIRONA

Near-Term Outlook Bleak for Medical Dental Supplies Industry

Bayer AG

eBay

Helen of Troy

Parker-Hannifin

While P/E alone fails to identify a true value stock, PEG helps to find the intrinsic value of a stock.

5 PEG-Based Value Stocks to Buy Amid the Coronavirus Crisis

Let's keep a watch on three stocks that are focused on offering advanced diagnostic testing to fight against coronavirus.

Diagnostic Testing Remains Crucial in Combatting Coronavirus

LabCorp's (LH) Covance business benefits from collaborations with leading pharmaceutical and biotechnology companies.

LabCorp's New Website Offers Patients Coronavirus Trial Details

LabCorp (LH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

News for Labcorp Holdings Inc Stock (LH)